Vir Biotechnology CMO Phil Pang to leave at end of March 2024; successor search started

Vir Biotechnology, Inc.

Executive VP and Chief Medical Officer Phil Pang, M.D., Ph.D. departing at end of March 2024, citing family reasons.
Company has initiated a search for a new Chief Medical Officer.
No interim CMO named; transition expected by end of March 2024.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Phil Pang

Executive Vice President and Chief Medical Officer

VIR · Vir Biotechnology, Inc.

Effective: 2024-03-31
Filed: February 20, 2024, 6:59 PM ET

On February 20, 2024, Vir Biotechnology, Inc. (the “Company”) announced that Executive Vice President and Chief Medical Officer, Phil Pang, M.D., Ph.D. has decided to leave the Company at the end of March 2024 to spend more time with his family.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Phil Pang departed as Executive Vice President and Chief Medical Officer at Vir Biotechnology, Inc..

Action: decided to leave
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On February 20, 2024, Vir Biotechnology, Inc. (the “Company”) announced that Executive Vice President and Chief Medical Officer, Phil Pang, M.D., Ph.D. has decided to leave the Company at the end of March 2024 to spend more time with his family.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-040034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.